CEO Phil Serwin discusses the potential for in-licensing assets in 2025 and 2026. He also highlights the strategy for Motixafortide in solid tumor indications and assures a smooth transition post the sale of Effexta with no impact on sales.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing